James Berry, a researcher in the Neurological Clinical Research Institute at Massachusetts General Hospital, is working to build tools and identify biomarkers to improve clinical trial methodology. His goal is to speed up the process of identifying the next drug that will slow, reverse or even prevent ALS in the future